Novartis Animal Health launched Onsior (robenacoxib) tablets, a three-day non-steroidal anti-inflammatory drug for postoperative cats, the Greensboro, N.C.-based company reported today.
The drug is indicated control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration. It is the first multi-dose oral NSAID approved for cats, Novartis reported.
The drug’s short blood half-life causes the active ingredient to be quickly eliminated from the blood while persisting longer at the site of inflamed tissue, allowing for once-a-day administration for up to three days, the company reported.
Side effects observed during a clinical field trial and six-month safety study included surgical site bleeding, infected surgery sites, lethargy, vomiting and lack of appetite in cats. The drug is indicated for cats 5.5 lbs. and heavier and 6 months old or older for a maximum of three days. The drug should not be used in cats that have a hypersensitivity to robenacoxib or known intolerance to NSAIDs and should not be administered in conjunction with any other oral or injectable NSAID or corticosteroid, according to Novartis.